Synovics Financial Statements From 2010 to 2025

SYVC Stock  USD 0.0001  0.00  0.00%   
Synovics Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Synovics Pharmaceuticals' valuation are provided below:
Gross Profit
4.5 M
Profit Margin
(0.26)
Market Capitalization
542.9 K
Enterprise Value Revenue
0.3837
Revenue
19.1 M
We have found one hundred twenty available fundamental trend indicators for Synovics Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Synovics Pharmaceuticals' current performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to 2,225. The current year's Enterprise Value is expected to grow to about 6.1 M

Synovics Pharmaceuticals Total Revenue

31.35 Million

Check Synovics Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Synovics Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 6.7 M or Total Revenue of 31.3 M, as well as many indicators such as Price To Sales Ratio of 1.0E-4, Dividend Yield of 0.0 or PTB Ratio of 4.0E-4. Synovics financial statements analysis is a perfect complement when working with Synovics Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Synovics Stock
Check out the analysis of Synovics Pharmaceuticals Correlation against competitors.
For information on how to trade Synovics Stock refer to our How to Trade Synovics Stock guide.

Synovics Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.7 M25.7 M21 M
Slightly volatile
Other Current Liabilities418 K440 K423.3 K
Slightly volatile
Total Current Liabilities9.5 M15.5 M12.7 M
Slightly volatile
Total Stockholder Equity2.8 M3.8 M3.9 M
Very volatile
Accounts Payable7.2 M6.9 M5.8 M
Slightly volatile
Cash72.1 K75.9 K107.4 K
Slightly volatile
Inventory3.5 M3.3 M2.8 M
Slightly volatile
Other Current Assets255.1 K433.6 K353.2 K
Slightly volatile
Total Liabilities12.7 M19.9 M16.3 M
Slightly volatile
Intangible Assets506.3 K533 K466 K
Slightly volatile
Common Stock22.4 K44 K36.6 K
Very volatile
Property Plant EquipmentM2.9 M2.4 M
Slightly volatile
Preferred Stock Total Equity883.5 K952.2 K837.4 K
Slightly volatile
Other Assets858.7 K903.9 K799.4 K
Slightly volatile
Long Term DebtM4.1 M3.6 M
Slightly volatile
Other Stockholder Equity10.8 M10.3 M8.6 M
Slightly volatile
Deferred Long Term Liabilities763.1 K803.2 K688.8 K
Slightly volatile
Long Term Investments981.5 K1.1 M1.2 M
Slightly volatile
Short and Long Term Debt3.9 M2.4 M2.2 M
Slightly volatile
Total Current Assets5.7 M8.2 M6.7 M
Slightly volatile
Short Term Debt3.9 M2.4 M2.2 M
Slightly volatile
Other Liabilities731.1 K762.6 K843.1 K
Slightly volatile
Net Receivables3.4 M4.4 M3.7 M
Slightly volatile
Good Will9.2 M10.3 M11.2 M
Slightly volatile

Synovics Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative6.7 M11.8 M9.7 M
Pretty Stable
Total Revenue31.3 M29.9 M24.9 M
Slightly volatile
Gross Profit10.8 M10.3 M8.6 M
Slightly volatile
Research Development984.8 K1.4 M1.1 M
Slightly volatile
Cost Of Revenue20.5 M19.5 M16.3 M
Slightly volatile
Total Operating Expenses21.5 M32.7 M26.6 M
Slightly volatile

Synovics Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditures855.3 K814.6 K680 K
Slightly volatile
Change To Liabilities499.9 K476.1 K425 K
Slightly volatile
Other Cashflows From Investing Activities120 K135 K147.2 K
Slightly volatile
Depreciation374.8 K703.1 K566.1 K
Slightly volatile
Change To Operating Activities681.8 K717.7 K638.2 K
Pretty Stable
Change To Netincome4.7 M5.2 M4.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.0E-41.0E-48.0E-4
Slightly volatile
PTB Ratio4.0E-44.0E-44.0E-4
Slightly volatile
Days Sales Outstanding11161.7776.155
Slightly volatile
Book Value Per Share0.230.240.3447
Slightly volatile
Average Payables1.7 M1.8 M1.6 M
Slightly volatile
Capex To Depreciation1.821.331.3468
Pretty Stable
PB Ratio4.0E-44.0E-44.0E-4
Slightly volatile
Inventory Turnover3.715.275.5592
Very volatile
Days Of Inventory On Hand53.356.1163.4073
Slightly volatile
Payables Turnover2.043.272.754
Pretty Stable
Average Inventory2.3 M2.2 M2.3 M
Slightly volatile
Research And Ddevelopement To Revenue0.03880.04082.0004
Slightly volatile
Capex To Revenue0.02330.02460.3124
Slightly volatile
Cash Per Share0.00310.00320.1561
Slightly volatile
Days Payables Outstanding110116131
Slightly volatile
EV To Operating Cash Flow2.031.931.7752
Pretty Stable
EV To Free Cash Flow2.482.372.1308
Pretty Stable
Intangibles To Total Assets0.240.480.4825
Very volatile
Current Ratio1.010.610.9113
Slightly volatile
Receivables Turnover9.56.126.5628
Slightly volatile
Shareholders Equity Per Share0.230.240.3447
Slightly volatile
Debt To Equity1.241.181.2185
Slightly volatile
Capex Per Share0.03290.03460.0311
Pretty Stable
Average Receivables2.5 M2.4 M2.6 M
Pretty Stable
Revenue Per Share1.040.991.0232
Slightly volatile
Interest Debt Per Share0.260.250.265
Slightly volatile
Debt To Assets0.220.260.2699
Pretty Stable
Operating Cycle127133138
Slightly volatile
Price Book Value Ratio4.0E-44.0E-44.0E-4
Slightly volatile
Days Of Payables Outstanding110116131
Slightly volatile
Ebt Per Ebit1.341.451.5787
Slightly volatile
Company Equity Multiplier4.224.024.2187
Slightly volatile
Long Term Debt To Capitalization0.50.480.3986
Slightly volatile
Total Debt To Capitalization0.370.510.5182
Pretty Stable
Debt Equity Ratio1.241.181.2185
Slightly volatile
Quick Ratio0.350.360.6798
Slightly volatile
Net Income Per E B T0.891.021.112
Slightly volatile
Cash Ratio0.00530.00560.3835
Slightly volatile
Days Of Inventory Outstanding53.356.1163.4073
Slightly volatile
Days Of Sales Outstanding11161.7776.155
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.210.940.863
Pretty Stable
Price To Book Ratio4.0E-44.0E-44.0E-4
Slightly volatile
Fixed Asset Turnover8.819.419.6492
Slightly volatile
Debt Ratio0.220.260.2699
Pretty Stable
Price Sales Ratio1.0E-41.0E-48.0E-4
Slightly volatile
Asset Turnover1.11.051.0785
Slightly volatile
Price Fair Value4.0E-44.0E-44.0E-4
Slightly volatile

Synovics Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 K2.1 K2.2 K
Slightly volatile

About Synovics Pharmaceuticals Financial Statements

Synovics Pharmaceuticals stakeholders use historical fundamental indicators, such as Synovics Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Synovics Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Synovics Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Synovics Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Synovics Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue29.9 M31.3 M
Cost Of Revenue19.5 M20.5 M
Research And Ddevelopement To Revenue 0.04  0.04 
Capex To Revenue 0.02  0.02 
Revenue Per Share 0.99  1.04 
Ebit Per Revenue(0.09)(0.09)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Synovics Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Synovics Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Synovics Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Synovics Pharmaceuticals Stock:
Check out the analysis of Synovics Pharmaceuticals Correlation against competitors.
For information on how to trade Synovics Stock refer to our How to Trade Synovics Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Synovics Pharmaceuticals. If investors know Synovics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Synovics Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share
0.683
Quarterly Revenue Growth
(0.80)
Return On Assets
(0.13)
Return On Equity
(3.14)
The market value of Synovics Pharmaceuticals is measured differently than its book value, which is the value of Synovics that is recorded on the company's balance sheet. Investors also form their own opinion of Synovics Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Synovics Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Synovics Pharmaceuticals' market value can be influenced by many factors that don't directly affect Synovics Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Synovics Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Synovics Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Synovics Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.